Bacainn Therapeutics
Business Services · 1-10 Employees
View Company Info for Free
Overview
Phone Number
(781) 290-9076Website
www.bacainntherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Bacainn Therapeutics
Bacainn Therapeutics is developing novel therapies that target the innate immune system to address uncontrolled inflammation in serious gastrointestinal and respiratory diseases. The company embraces the latest insights into innate immunity to guide bold, new approaches for treating inflammatory diseases differently. Founded in 2017, Bacainn is funded by Morningside Ventures.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Bacainn Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Bacainn Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Bacainn Therapeutics
Bacainn Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Bacainn Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Bacainn Therapeutics has new funding data
Click to see if Bacainn Therapeutics had a recent Job posting/layoffs
Check out if Bacainn Therapeutics is spiking on competitors!
Product Launch: Get notified when Bacainn Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Bacainn Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Bacainn Therapeutics
Compare insights from companies similar to Bacainn Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Bacainn Therapeutics
<$5M
1-10
Private
-
2017
N/A
Company Profile Activity
Activity Insights
Bacainn Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Bacainn Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Bacainn Therapeutics.
Bacainn Therapeutics Tech Stack
A closer look at the technologies used by Bacainn Therapeutics
Bacainn Therapeutics News & Media
Bacainn Therapeutics Presents at ECCO ‘21 Results from Phase 1 Study that Shows BT051, an Oral, Locally-Acting Inhibitor of Neutrophil Trafficking and Activity, Is Safe and Well-Tolerated in Healthy Adults
CONCORD, Mass.--(BUSINESS WIRE)--Bacainn Therapeutics, Inc., a biotechnology company focused on developing novel therapies that target the innate immune system to address uncontrolled inflammation, today presented results at the European Crohn’s and Colitis Organisation’s 2021 Virtual Congress from a Phase 1 study that showed its lead asset BT051 was safe and well-tolerated in healthy adults. BT051 is an oral, locally-acting inhibitor of neutrophil trafficking and activation and is in clinicalBacainn Therapeutics Reports Positive Topline Results from Phase 1 Study of BT051, a Novel Therapeutic Approach to Treat Inflammatory Diseases Such As Ulcerative Colitis
CONCORD, Mass.--(BUSINESS WIRE)--Bacainn Therapeutics, Inc., a Company developing novel therapies to address uncontrolled inflammation, today announced the successful completion of the company’s Phase 1, first-in-human clinical trial of BT051, a novel, orally administered, gut-selective inhibitor of migration and activation of neutrophils. During active flares of ulcerative colitis, neutrophils migrate into the submucosa and lumen of the colon where they contribute to tissue damage by releasingBacainn Therapeutics Announces IND Clearance for BT051 and Initiation of Phase 1 Clinical Trial, Bacainn’s First Clinical Candidate for the Treatment of Ulcerative Colitis
CONCORD, Mass.--(BUSINESS WIRE)--Bacainn Therapeutics, Inc., a Company developing novel therapies to address uncontrolled inflammation, announced today FDA’s Clearance of the IND for BT051, and initiation of a Phase 1 Clinical Trial with patient dosing expected in the coming months. BT051 is a first-in-class approach to modulating the migration and activation of specific innate immune cells (neutrophils) and is being developed to treat various acute medical conditions including ulcerative colit
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Bacainn Therapeutics
Sign Up For FreeTo access detailed company insights
Bacainn Therapeutics is developing novel therapies that target the innate immune system to address uncontrolled inflammation in serious gastrointestinal and respiratory diseases. The company embraces the latest insights into innate immunity to guide bold, new approaches for treating inflammatory diseases differently. Founded in 2017, Bacainn is fun... Read More
